Latest news with #IndocoRemediesLimited
Business Upturn
24-07-2025
- Business
- Business Upturn
Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore
Indoco Remedies Limited reported a net loss of Rs 3.64 crore for the quarter ended June 30, 2025 (Q1FY26), compared to a profit of Rs 1.82 crore in the corresponding quarter last year. This marks the second consecutive quarter of losses, as the company had posted a Rs 4.13 crore loss in Q4FY25. Revenue from operations in Q1FY26 stood at Rs 42.91 crore, up marginally from Rs 42.43 crore reported in Q1FY25. Including other operating income of Rs 8.81 crore, total income for the quarter reached Rs 43.79 crore. With additional other income of Rs 1.63 crore, total income was Rs 43.95 crore, a slight increase from Rs 43.25 crore YoY. Despite the revenue uptick, expenses surged significantly to Rs 47.62 crore in Q1FY26, up from Rs 42.56 crore in the same quarter last year. Key cost drivers included higher raw material costs (Rs 10.55 crore), employee expenses (Rs 10.7 crore), and other operating expenses (Rs 15.67 crore). Finance costs also increased to Rs 2.61 crore from Rs 1.43 crore YoY. The company reported a loss before tax of Rs 3.66 crore, with no exceptional items during the quarter. Tax expenses for the quarter were negligible, resulting in a final net loss of Rs 3.64 crore. The results highlight the pressure Indoco Remedies is facing despite stable revenues, with rising costs weighing heavily on profitability. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
03-06-2025
- Business
- Business Upturn
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
By Aditya Bhagchandani Published on June 3, 2025, 13:06 IST Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a significant development for the company as it expands its international portfolio in the antiplatelet medication segment. The newly launched product is aimed at reducing the risk of heart attacks, strokes, and other cardiovascular complications. It will be marketed and distributed across the UK by Clarity Pharma. Commenting on the development, Aditi Kare Panandikar, Managing Director of Indoco Remedies, said, 'This development underscores our commitment to bringing high quality, life-saving treatments to patients in the UK.' Indoco Remedies is a fully integrated pharmaceutical company with a global presence and a turnover of USD 180 million. The company has 11 manufacturing facilities and over 6,000 employees. It operates in various therapeutic segments, including gastrointestinal, respiratory, anti-infectives, and cardiovascular care, among others. The UK launch of Ticagrelor further strengthens Indoco's footprint in the international market and reinforces its commitment to expanding its presence in regulated markets. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
23-05-2025
- Business
- Business Upturn
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
By Aman Shukla Published on May 23, 2025, 11:20 IST Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The approved product is a generic version of Zyloprim® 200 mg, originally marketed by Casper Pharma LLC. Allopurinol is commonly prescribed to manage high levels of uric acid in the blood, a condition known as hyperuricemia. It is also used to control uric acid levels in patients undergoing cancer treatment or those with kidney stones, where elevated uric acid can cause further complications. The approved product will be manufactured at Indoco Remedies' production facility located at L-14, Verna Industrial Area, Verna, Goa – 403722, India. Aditi Panandikar, Managing Director, commented, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' This approval allows Indoco Remedies to market Allopurinol Tablets USP 200 mg in the U.S. market, providing a therapeutic alternative for patients and contributing to the availability of cost-effective generic medications. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
